ParvOryx

The clinical development of ParvOryx started in Q3 2011. The Phase I/IIa trial is designed to treat patients with primary or recurrent glioblastoma multiforme using parvovirus H1. This trial is open-labeled and conducted at single center.

Primary objectives of the trial are safety, maximum tolerated dose, viremia and virus shedding.

Secondary objectives are efficacy, progression-free survival up to six months and overall survival.

For more information see: Mode of action of parvovirus H1 and ClinicalTrials.gov